Benefits of Menopausal Hormone Therapy The benefits of menopausal hormone therapy

Menopause is not a pathological, but quite a normal life event. Still, declining hormone production can essentially disturb the quality of woman’s life, with physical and emotional consequences, and, which is more important, it may potentiate the development of additional health risks, such as cardiovascular diseases and osteoporosis already present in women of older age. The aim of this article is to present current treatment of perimenopausal problems.

[1]  B. Komm,et al.  Selective estrogen receptor modulators in clinical practice: a safety overview , 2015, Expert opinion on drug safety.

[2]  D. Archer,et al.  17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. , 2015, Maturitas.

[3]  C. Peterson,et al.  Thermosensitive Progesterone Hydrogel: A Safe and Effective New Formulation for Vaginal Application , 2015, Pharmaceutical Research.

[4]  J. Pinkerton.  What are the concerns about custom-compounded "bioidentical" hormone therapy? , 2014, Menopause.

[5]  B. Komm,et al.  Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss , 2014, Steroids.

[6]  M. Murad,et al.  Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[7]  B. Komm,et al.  An overview of current and emerging SERMs , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  B. Komm,et al.  Differential effects of menopausal therapies on the endometrium , 2014, Menopause.

[9]  A. Gompel,et al.  Updated 2013 international menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health , 2014 .

[10]  J. Simon,et al.  Endometrial Safety of Ospemifene and the Ability of Transvaginal Ultrasonography to Detect Small Changes in Endometrial Thickness , 2014 .

[11]  M. Savvas,et al.  What should we be advising women about hormone replacement therapy? , 2014 .

[12]  L. Shuster,et al.  Prescribing menopausal hormone therapy: an evidence-based approach , 2014, International journal of women's health.

[13]  B. Komm,et al.  Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  C. Gracia.  Practice Bulletin No. 141: Management of Menopausal Symptoms , 2014, Obstetrics and gynecology.

[15]  B. Komm,et al.  Tissue-selective estrogen complexes for postmenopausal women. , 2013, Maturitas.

[16]  M. L'hermite.  HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT , 2013, Climacteric : the journal of the International Menopause Society.

[17]  M. Savvas,et al.  The 2013 British Menopause Society & Women’s Health Concern recommendations on hormone replacement therapy , 2013, Menopause international.

[18]  R. Lobo,et al.  Global Consensus Statement on menopausal hormone therapy. , 2013, Maturitas.

[19]  R. Kagan.  The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. , 2012, Journal of women's health.

[20]  V. Henderson,et al.  Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on , 2012, Climacteric : the journal of the International Menopause Society.

[21]  J. Simon,et al.  What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone , 2012, Climacteric.

[22]  M. Goodman.  Are all estrogens created equal? A review of oral vs. transdermal therapy. , 2012, Journal of women's health.

[23]  M. Beckmann,et al.  Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy , 2012, Breast Cancer Research.

[24]  J. Levine.  Treating menopausal symptoms with a tissue-selective estrogen complex. , 2011, Gender medicine.

[25]  A. Shelling.  Premature ovarian failure. , 2010, Reproduction.

[26]  E. Gold,et al.  Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). , 2010, Archives of General Psychiatry.

[27]  V. Vogel.  The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.

[28]  S. Steel,et al.  The effects of short-term hormone replacement therapy on long-term bone mineral density , 2007, Climacteric : the journal of the International Menopause Society.

[29]  R. Rizzoli.  Prevention of Osteoporosis , 2006 .

[30]  R. Wallace,et al.  Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. , 2006, Arthritis and rheumatism.

[31]  Garnet L Anderson,et al.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. , 2006, JAMA.

[32]  M. Gojnic,et al.  [Effects of tibolone on the risk factors for cardiovascular diseases in postmenopausal women]. , 2006, Vojnosanitetski pregled.

[33]  P. Langhorne,et al.  Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review , 2005, Thrombosis and Haemostasis.

[34]  S. Vujović,et al.  [Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure]. , 2005, Medicinski pregled.

[35]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[36]  F. Riphagen.  Intrauterine application of progestins in hormone replacement therapy: a review , 2000, Climacteric : the journal of the International Menopause Society.

[37]  C C Glüer,et al.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. , 1999, JAMA.

[38]  J. Rosenberg.  [Postmenopausal hormone therapy]. , 1987, Ugeskrift for læger.

[39]  Atividade Física,et al.  American College of Obstetricians and Gynecologists , 1979, Journal of the American Dietetic Association.

[40]  E. Fels.  [Androgen therapy in women]. , 1950, Prensa medica argentina.

[41]  J. Pinkerton.  The 2017 hormone therapy position statement of The North American Menopause Society. , 2017, Menopause.

[42]  A. D. Ruiz,et al.  The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study. , 2014, International journal of pharmaceutical compounding.

[43]  M. Vasiljević,et al.  [Comparison of two different types of hormone therapy effects on haemostatic parameters in early postmenopausal women]. , 2011, Srpski arhiv za celokupno lekarstvo.

[44]  A. Neskovic,et al.  [Atherosclerosis plaque regression]. , 2006, Medicinski pregled.

[45]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[46]  V. Jordan,et al.  Send Orders of Reprints at Reprints@benthamscience.net the Discovery and Development of Selective Estrogen Receptor Modulators (serms) for Clinical Practice the Biological Basis of Serm Action: Target Tissue Specific Actions , 2022 .